Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.

被引：6
|
作者：
Tam, Constantine Si Lun
Roberts, Andrew Warwick
Anderson, Mary Ann
Dawson, Sarah-Jane
Hicks, Rodney J.
Burbury, Kate
Turner, Gillian
Di Iulio, Juliana
Bressel, Mathias
Westerman, David A.
Agarwal, Rishu
Pott, Christiane
Dreyling, Martin H.
Dawson, Mark A.
Seymour, John Francis
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7520
引用
收藏
页数：6
相关论文
共 50 条
  • [41] CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study
    Minson, Adrian
    Hamad, Nada
    Cheah, Chan Y.
    Tam, Constantine
    Blombery, Piers
    Westerman, David
    Ritchie, David
    Morgan, Huw
    Holzwart, Nicholas
    Lade, Stephen
    Anderson, Mary Ann
    Khot, Amit
    Seymour, John F.
    Robertson, Molly
    Caldwell, Imogen
    Ryland, Georgina
    Saghebi, Javad
    Sabahi, Zahra
    Xie, Jing
    Koldej, Rachel
    Dickinson, Michael
    BLOOD, 2024, 143 (08) : 673 - 684
  • [42] Primary Results from Phase 3, Double-Blind, Placebo-Controlled SHINE Trial: Ibrutinib (Ibr) in Combination with Bendamustine-Rituximab (BR) and R-Maintenance as First-Line Treatment (1L) in Elderly Patients with Mantle Cell Lymphoma (MCL)
    Dreyling, M.
    Jurczak, W.
    Jerkeman, M.
    Trotman, J.
    Zinzani, P. L.
    Belada, D.
    Boccomini, C.
    Flinn, I. W.
    Giri, P.
    Goy, A.
    Hamlin, P. A.
    Hermine, O.
    Hernandez-Rivas, J. -A
    Hong, X.
    Kim, S. J.
    Lewis, D.
    Mishima, Y.
    Oezcan, M.
    Perini, G. F.
    Pocock, C.
    Song, Y.
    Spurgeon, S. E.
    Storring, J. M.
    Walewski, J.
    Zhu, J.
    Qin, R.
    Henninger, T.
    Deshpande, S.
    Howes, A.
    Le, Gouill S.
    Wang, M. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 149 - 150
  • [43] Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study
    Tam, Constantine S.
    Ramchandren, Radhakrishnan
    Chen, Robert
    Karlin, Lionel
    Chong, Geoffrey
    Jurczak, Wojciech
    Wu, Ka Lung
    Bishton, Mark
    Collins, Graham P.
    Eliadis, Paul
    Peyrade, Frederic
    Szafer-Glusman, Edith
    Lee, Yihua
    Eckert, Karl
    Neuenburg, Jutta K.
    Wang, Michael
    BLOOD, 2020, 136
  • [44] Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma
    Jiang, Huijuan
    Lwin, Tint
    Zhao, Xiaohong
    Ren, Yuan
    Li, Grace
    Moscinski, Lynn
    Shah, Bijal
    Tao, Jianguo
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 298 - 302
  • [45] Venetoclax As a Single Agent and in Combination with PI3K-mTOR1 /2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma
    Jiang, Huijuan
    Lwin, Tint
    Shah, Bijal D.
    Li, Grace T.
    Ren, Yuan
    Yan, Michael W.
    Moscinski, Lynn C.
    Zhao, Xiaohong
    Tao, Jianguo
    BLOOD, 2017, 130
  • [46] Phase lb/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naive Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Phelan, James D.
    Muppidi, Jagan R.
    Gordon, Max J.
    Yang, Yandan
    Xu, Weihong
    Davies-Hill, Theresa
    Huang, Da Wei
    Thomas, Craig J.
    Ceribelli, Michele
    Tosto, Frances A.
    Juanitez, Anna M.
    Pradhan, Amynah
    Morrison, Candis
    Tadese, Atekelt
    Ramsower, Colleen
    Rimsza, Lisa M.
    Jacob, Allison P.
    Simmons, Heidi
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    BLOOD, 2024, 144 : 750 - 751
  • [47] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
    Wierda, William G.
    Tam, Constantine S.
    Allan, John N.
    Siddiqi, Tanya
    Kipps, Thomas J.
    Opat, Stephen
    Tedeschi, Alessandra
    Badoux, Xavier C.
    Kuss, Bryone J.
    Jackson, Sharon
    Moreno, Carol
    Jacobs, Ryan
    Pagel, John M.
    Flinn, Ian W.
    Zhou, Cathy
    Szafer-Glusman, Edith
    Ninomoto, Joi
    Dean, James P.
    James, Danelle F.
    Ghia, Paolo
    BLOOD, 2020, 136
  • [48] Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).
    Wang, Michael
    Jurczak, Wojciech
    Jerkeman, Mats
    Trotman, Judith
    Zinzani, Pier Luigi
    Walewski, Jan Andrzej
    Zhu, Jun
    Spurgeon, Stephen
    Goy, Andre
    Hamlin, Paul A.
    Belada, David
    Ozcan, Muhit
    Storring, John
    Lewis, David John
    Rivas, Jose Angel Hernandez
    Henninger, Todd
    Deshpande, Sanjay
    Qin, Rui
    Le Gouill, Steven
    Dreyling, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [49] Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
    Lee, Hun Ju
    Choi, Michael Y.
    Siddiqi, Tanya
    Wierda, William G.
    Claudia Barrientos, Jacqueline
    Lamanna, Nicole
    Goldenberg, Alec
    Isufi, Iris
    Tuscano, Joseph M.
    Subbiah, Suki
    Weihe, Elizabeth Kristine
    Ianopulos, Xen
    Breitmeyer, James Bradley
    Hsu, Frank J.
    Wang, Michael
    Jamieson, Catriona Hm
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)
    Portell, Craig A.
    Jegede, Opeyemi
    Bennani, N. Nora
    Naik, Seema
    Reynolds, Christopher M.
    Patel, Priyank P.
    Robertson, Michael J.
    Kahl, Brad S.
    BLOOD, 2023, 142
12345